Renue Life Sciences, Inc. — SEC Form D Filing

Renue Life Sciences, Inc. filed an SEC Form D on October 14, 2026, reporting $250K raised in EdTech.

Form D filing details

Filing
SEC Form D
Filing date
October 14, 2026
Amount reported
$250K
Round stage
Seed
Industry
EdTech
Website
https://renue.bio/

What the company does

Securities: Issuance of Simple Agreements for Future Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

People face age-related diseases, cellular degeneration, and declining immunity, along with other complex diseases, which are currently addressed through reactive treatment approaches.

Solution

Renue Life Sciences is developing next-generation therapies for these conditions by integrating AI-driven computation, gene compensation, and cellular reprogramming to restore function at the molecular level and achieve proactive cellular restoration.

Why now

The increasing complexity of various industries and the need for continuous upskilling, combined with the demand for flexible and accessible learning solutions, makes a robust e-learning platform essential.

Verdict

This cleared because the initial capital commitment was low, allowing for a speculative bet on the *idea* of next-generation therapies, not because the EdTech classification provided clear market access. Investors implicitly funded a long-shot R&D vision where future therapeutic IP could command significant value. This limited upside, however, as the capital amount itself suggested this was an exploration of feasibility, not a scaling of proven demand or market fit.

Source: SEC EDGAR Form D filing